Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Open accessAbstract
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.3,4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity.5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Real-life data from the United States has shown that only 56% of NAFLD patients with at least one indication for statin therapy were actually prescribed statins.
“Although, probably due to concerns about safety and statin use in chronic liver disease patients, real‐life data from the United States has shown that only 56% of NAFLD patients with at least one indication for statin therapy were actually prescribed statins [92].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 8
- [1]Taylor F, Huffman MD, Macedo AF, Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013: CD004816. 23440795 PMC6481400
- [2]Lewis JH, Mortensen ME, Zweig S, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453– 63. 17668878
- [3]Kaplan DE, Serper MA, Mehta R, Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019; 156: 1693– 1706 e12. 30660733
- [4]Kim RG, Loomba R, Prokop LJ, Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2017; 15: 1521– 1530. e8. 28479502 PMC5605397
- [5]Del Ben M, Baratta F, Polimeni L, Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2017; 27: 161– 167. 27914698
- [6]Stone NJ, Robinson JG, Lichtenstein AH, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889– 934. 24239923
- [7]Barritt ASt, Gitlin N, Klein S, Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials 2017; 61: 33– 38. 28735109
- [8]Kaplan DE. The Use of Statins in Patients With Cirrhosis. Gastroenterol Hepatol (N Y) 2018; 14: 485– 487. 30302064 PMC6170890
Cited by
Sorted by citations
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305 · see citing works
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ayada, I., van Kleef, L. A., Zhang, H., Liu, K., Li, P., Abozaid, Y. J., Lavrijsen, M., Janssen, H. L. A., van der Laan, L. J. W., Ghanbari, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104392 · Cited by 117 · see citing works
Zhang, J., Fu, S., Liu, D., Wang, Y., & Tan, Y. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002517 · Cited by 27 · see citing works
- Authors
- Thomson, M. J., Serper, M., Khungar, V., Weiss, L. M., Trinh, H., Firpi-Morell, R., Roden, M., Loomba, R., Barritt, A. S., Gazis, D., Mospan, A. R., Fried, M. W., Reddy, K. R., & Lok, A. S.
- Affiliations
- University of Minnesota (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Düsseldorf University Hospital (DE)
- University of California San Diego (US)
- University of North Carolina at Chapel Hill (US)
- Target PharmaSolutions, Inc. (United States) (US)
- University of Michigan (US)
- Corresponding author
- Lok, Anna S.
- ORCID
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 20
- Issue
- 2
- Pages
- 458-460.e4
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC8464616
- OpenAlex
- W3147609187
- Cited by
- 38
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 11 · 2022: 10 · 2021: 2
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (1K23DK1158907-03)
- Inventiva Pharma
- Boehringer Ingelheim
- Intercept Pharmaceuticals
- Eli Lilly and Company
- Novo Nordisk
- Novartis
- Servier
- Gilead Sciences
- Sanofi
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin use, non-alcoholic fatty liver disease, statin prescribing, cardiovascular risk, statins, underprescribing, real-world prescribing patterns
- MeSH terms
- Humans, Liver Cirrhosis, Liver Neoplasms, Prevalence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
